Clincosm LogoSign in Get a demo

Hepatocellular Carcinoma

Showing NaN - NaN of 148
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Shanghai ([68Ga]Ga-NOTA-RG2 PET Imaging)

Recruiting
  • Hepatocellular Carcinoma
  • [68Ga]Ga-NOTA-RG2 PET Imaging
  • Shanghai, China
    Huashan Hospital
Nov 19, 2023

Hepatocellular Carcinoma Trial in Shanghai (BC3402 injection, Durvalumab injection)

Not yet recruiting
  • Hepatocellular Carcinoma
  • BC3402 injection
  • Durvalumab injection
  • Shanghai, China
    Zhongshan Hospital, Fudan University
Oct 26, 2023

Hepatocellular Carcinoma Trial in Shanghai (Anlotinib and TQB2450)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Anlotinib and TQB2450
  • Shanghai, Shanghai, China
    Zhongshan hospital
Sep 4, 2023

Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Nanjing, Jiangsu, China
  • +1 more
Jul 28, 2023

Postoperative Outcomes in Chinese HCC Patients Treated With

Recruiting
  • Hepatocellular Carcinoma
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Aug 1, 2023

    Hepatocellular Carcinoma Trial in Shanghai (CAR-GPC3 T cells)

    Recruiting
    • Hepatocellular Carcinoma
    • CAR-GPC3 T cells
    • Shanghai, China
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
    Jun 22, 2023

    Hepatocellular Carcinoma Trial in Shanghai (Cadonilimab+TACE)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • Shanghai, Shanghai, China
      Eastern hepatobilliary surgery hospital
    Jun 21, 2023

    Hepatocellular Carcinoma Trial in Shanghai (M-TACE)

    Enrolling by invitation
    • Hepatocellular Carcinoma
    • M-TACE
    • Shanghai, Shanghai, China
      Department of Interventional Radiology, Zhongshan Hospital, Fuda
    May 24, 2023

    Hepatocellular Carcinoma Trial in China (Anlotinib HCl capsules, Penpulimab injection, Anlotinib HCl capsules -matching ,

    Recruiting
    • Hepatocellular Carcinoma
    • Anlotinib hydrochloride capsules, Penpulimab injection
    • Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
    • Bengbu, Anhui, China
    • +66 more
    May 15, 2023

    Hepatocellular Carcinoma, Biliary Tract Cancer Trial in Worldwide (MEDI5752, Bevacizumab, Lenvatinib)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Biliary Tract Cancer
    • Birmingham, Alabama
    • +44 more
    Mar 17, 2023

    Liver Cancer, Hepatocellular Carcinoma, Resistant Cancer Trial in Shanghai (Lenvatinib Oral Product Plus VIC1911)

    Not yet recruiting
    • Liver Cancer
    • +2 more
    • Lenvatinib Oral Product Plus VIC1911
    • Shanghai, China
      Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine,
    Jan 30, 2023

    Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

    Recruiting
    • Hepatocellular Carcinoma
    • Shanghai, China
      Zhongshan Hospital Fudan university
    Jan 31, 2023

    Hepatocellular Carcinoma Trial in Worldwide (Sitravatinib, Tislelizumab, sitravatinib-matching )

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Bengbu, Anhui, China
    • +81 more
    Feb 1, 2023

    Liver Tumor, Hepatocellular Carcinoma Trial in Guangzhou, Beijing, Shanghai (Microwave ablation)

    Active, not recruiting
    • Liver Tumor
    • Hepatocellular Carcinoma
    • Microwave ablation
    • Guangzhou, Guangdong, China
    • +3 more
    Jan 23, 2023

    Hepatocellular Carcinoma Trial in Worldwide (Nivolumab, Ipilimumab, Sorafenib)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • Tucson, Arizona
    • +209 more
    Jan 17, 2023

    Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
    • TACE
    • Nanjing, China
    • +1 more
    Dec 28, 2022

    Hepatocellular Carcinoma Trial in Shanghai (Ori-C101)

    Recruiting
    • Hepatocellular Carcinoma
    • Ori-C101
    • Shanghai, China
      Zhongshan Hospital Fudan University
    Dec 21, 2022

    Hepatocellular Carcinoma Trial in Worldwide (drug, other, procedure)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • Mobile, Alabama
    • +182 more
    Dec 1, 2022

    Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult Trial in Worldwide (Nivolumab, Relatlimab)

    Recruiting
    • Hepatocellular Carcinoma
    • +4 more
    • Nivolumab
    • Relatlimab
    • Ciudad de Buenos Aires, Buenos Aires, Argentina
    • +74 more
    Nov 11, 2022

    Hepatocellular Carcinoma Trial in China, United States (CS1003+Lenvatinib, CS1003 Placebo+Lenvatinib)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • Nofazinlimab (CS1003)+Lenvatinib
    • Nofazinlimab (CS1003) Placebo+Lenvatinib
    • Coronado, California
    • +5 more
    Nov 7, 2022

    Hepatocellular Carcinoma Trial (TACE+Camrelizumab+Apatinib mesylate, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • TACE+Camrelizumab+Apatinib mesylate
    • TACE
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Oct 17, 2022

    Hepatocellular Carcinoma Trial in Shanghai (IBI310, Sintilimab, Sorafenib)

    Recruiting
    • Hepatocellular Carcinoma
    • Shanghai, Shanghai, China
      Fudan Universtiy Zhongshan Hospital
    Sep 16, 2022

    Hepatocellular Carcinoma Trial in Worldwide (Durvalumab, Bevacizumab, Placebo)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • Birmingham, Alabama
    • +213 more
    Aug 19, 2022

    Hepatocellular Carcinoma Trial in Shanghai (laparoscopic hepatectomy, Open hepatectomy)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • laparoscopic hepatectomy
    • Open hepatectomy
    • Shanghai, China
      Huashan hospital
    Aug 16, 2022

    Hepatocellular Carcinoma Trial in Shanghai (PD-1 and Lenvatinib Plus TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • PD-1 and Lenvatinib Plus TACE
    • Shanghai, Shanghai, China
      Huashan hospital
    Aug 16, 2022